Doxycycline vs. Penicillin G Benzathine for the Treatment of Syphilis in Patients with HIV

Authors

  • Andrew Cole Eichelberger 4052265810
  • Isaac Nichols
  • Bryan Bozell

Abstract

Background: Syphilis is a highly prevalent sexually transmitted infection that can cause severe health complications if not treated effectively. Penicillin G benzathine is the standard treatment, while doxycycline serves as an alternative for patients with penicillin allergies. However, data on the efficacy of doxycycline in patients with concomitant human immunodeficiency virus (HIV) remain limited. This study aimed to compare the effectiveness of penicillin G benzathine and doxycycline in treating syphilis in HIV-positive patients.  

Methods: This retrospective cohort study reviewed electronic medical records of patients diagnosed with both syphilis and HIV from October 2020 to July 2022 at an urban outpatient HIV specialty clinic. Patients were included if they received either penicillin G benzathine or doxycycline. The primary endpoint was syphilis resolution, defined as a four-fold decrease in rapid plasma reagin (RPR) titers at 12 months. Secondary endpoints included co-infection rates and reported adverse effects. Statistical analysis was conducted using Fisher’s exact test.  

Results: Of 370 reviewed charts, 134 patients met inclusion criteria (113 penicillin G benzathine, 21 doxycycline). Syphilis resolution occurred in 103/113 (91.6%) patients in the penicillin group and 18/21 (85.7%) in the doxycycline group (p = 0.07). Adverse effects were minimal, with one case of nausea (penicillin) and one case of diarrhea (doxycycline).  

Conclusion: No statistically significant difference was observed between treatment groups, though penicillin showed a numerically higher resolution rate. Due to the small sample size, further research is needed to confirm the efficacy of doxycycline in this population.  

Downloads

Published

2025-05-14

Issue

Section

Pharmacotherapy